The rise of pills marketed for women’s confidence reveals the intersection of gender, medicine, capitalism, and the unfinished politics of liberation.

Confidence has long been a contested resource. For men, it is assumed; for women, it is prescribed. Across the twentieth century, women fought for the right to vote, to work, to control their bodies. By the twenty-first, another frontier emerged: the right to feel adequate in a world designed to diminish them. Now, in 2025, a pill promises to deliver what centuries of social conditioning have withheld—confidence. Marketed as a biochemical shortcut to self-assurance, it is the latest emblem of how gender, medicine, and capitalism intersect. But what does it mean when confidence itself is commodified? And why does the demand for such a pill tell us more about society’s failures than women’s shortcomings?
This is not simply a story about pharmacology. It is about power.
To understand the confidence pill, one must trace the lineage of how medicine has historically framed women. From “hysteria” in the nineteenth century to Prozac in the 1990s, the female body has been treated as a site of correction. Pills have been prescribed not only to treat illness but to manage behaviour, to conform women to systems never built for them. The contraceptive pill in the 1960s was revolutionary—granting women unprecedented control over reproduction. Yet even that liberation was framed within male-dominated institutions of science and commerce. The confidence pill is the latest iteration. It suggests that rather than dismantling systems that erode women’s self-assurance, society will provide capsules to compensate. The body must adapt, not the culture.
Pharmacologically, the pill in question combines mild stimulants with mood regulators designed to enhance dopamine and serotonin levels. Scientifically, it is not radically different from existing antidepressants or anti-anxiety medication. The difference lies in branding. It is sold not as treatment but as enhancement. Not as therapy but as empowerment. Glossy advertisements promise not relief from disorder but the arrival of confidence itself: “Be Bold. Be Fearless. Be You—Now in One Dose.” This reframing is crucial. The pharmaceutical industry has realised that aspiration sells better than pathology. Confidence is marketable. And in a culture saturated with self-help rhetoric, the promise of instant self-belief is irresistible.
The confidence pill thrives because capitalism excels at turning insecurity into profit. Beauty standards, workplace hierarchies, and social expectations generate the very anxieties that pills then claim to solve. A woman underpaid compared to male colleagues may feel inadequate. Rather than reform wage structures, society offers her a pill. A teenager pressured by Instagram perfection may feel inferior. Rather than regulate platforms, society offers her a capsule. The confidence pill is thus less about empowerment than about adaptation. It allows women to cope with unjust systems rather than transform them. In this sense, it is not liberation but pacification dressed as progress.
Confidence itself is complex. It is not merely biochemical. It is relational, social, cultural. It arises from recognition, opportunity, and respect. To suggest it can be swallowed is to reduce it to chemistry alone. Yet the appeal is undeniable. Confidence is currency in workplaces, in politics, in relationships. Women denied it structurally are understandably drawn to any means of levelling the field. The pill offers not only dopamine but hope.
But hope mediated through pharmacology is fragile. What happens when the pill wears off? What happens when reliance replaces resilience Feminist scholars are divided. Some argue that the confidence pill, like the contraceptive pill before it, expands agency. Women should have the choice to alter their neurochemistry if it empowers them. Others counter that it medicalises social injustice, making women responsible for overcoming barriers that society should dismantle. The ethical debate is profound. Does empowerment through chemistry reinforce the very systems it seeks to escape? Or is every tool valid in the fight for agency? The answer may be both. Liberation is rarely pure. Tools can be co-opted even as they empower.
Nowhere is the confidence pill more evident than in the workplace. Surveys show women increasingly turn to enhancement drugs before major presentations, interviews, or negotiations. Employers, often quietly complicit, benefit from the performance boost without addressing structural inequities. The risk is clear: confidence becomes another metric of productivity, another resource to be optimised. The woman who refuses the pill may be seen as lacking drive. Enhancement becomes expectation. Choice becomes coercion. In this way, the pill risks reproducing the very inequities it claims to remedy.
The phenomenon is not confined to America. In Asia, pills marketed for confidence blur with supplements promising beauty and slimness. In Europe, debates rage over whether such pills should be regulated as medicine or lifestyle products. In Africa and Latin America, access disparities highlight the global inequality of pharmacological empowerment. The global market for “confidence enhancers” is projected to reach billions. But access is stratified. Privileged women may buy empowerment in capsules. Marginalised women remain excluded, reinforcing the hierarchies of class and race. The confidence pill is part of a broader trend of human enhancement. Nootropics for focus, stimulants for productivity, psychedelics for creativity—the body is increasingly seen as a site of optimisation.
The danger is that humanity begins to outsource identity to chemistry. If confidence, creativity, and resilience are all medicated, what remains of the unaltered self? What happens to societies that demand perpetual enhancement? The risk is not only addiction to substances but addiction to the very idea that identity must be engineered to fit capitalism’s demands.
The pill women are taking for confidence matters not because it is revolutionary medicine, but because it symbolises a deeper crisis. It reveals a society more willing to prescribe adaptation than pursue justice. It shows how capitalism commodifies even the most intimate of human traits. It underscores how gendered inequities persist, repackaged as empowerment. This still matters because confidence should not be a pill. It should be a birthright of dignity, opportunity, and equality. Until society confronts the systems that erode women’s self-assurance, no capsule can deliver true empowerment. The question is not whether women should take the pill. The question is why society keeps forcing them to.
Anonymous is a private guest contributor of WTM MEDIA. Through Why These Matter, they examines the intersections of medicine, healthcare, and design—bringing clarity to issues that shape people, influence culture, and determine the future of global society.

The modern city has spent more than a century attempting to make water disappear. Rain falls onto roofs, roads and pavements. Gutters collect it. Drains capture it. Pipes bury it. Pumps move it. Rivers are channelled. Wetlands are filled. Coastlines are defended. The engineering objective has largely been straightforward: separate water from urban life as efficiently as possible. That model is reaching its limits. Around 600 million urban residents already live with significant annual flood hazard, according to the World Bank. Globally, 1.81 billion people live in flood-prone areas, while annual urban flood losses could approach $50 billion by 2050. Rapid urbanisation, ageing drainage infrastructure, land subsidence and changing rainfall patterns are interacting with the basic physical reality that cities have covered enormous portions of naturally absorbent ground with concrete and asphalt. Yet the consequential story is not simply that cities need bigger drains. A different philosophy of urban resilience is emerging: parks designed to flood temporarily; streets shaped to carry cloudbursts; wetlands restored as infrastructure; plazas capable of storing stormwater; permeable landscapes that absorb rainfall; buildings elevated or adapted to tolerate inundation; sensors that reveal water movement in real time; and neighbourhoods organised around the understanding that some water cannot — and perhaps should not — be engineered away. The World Bank increasingly describes effective urban flood management as an integration of grey infrastructure, green infrastructure, nature-based systems, planning, warning systems and institutional reform, rather than reliance on any single engineering intervention. The conceptual reversal is enormous. For generations, successful urbanisation meant controlling nature sufficiently to construct the city. The next generation of urbanism may require something more intelligent: designing the city so nature can still function inside it.

For much of the post-financial-crisis era, wealthy economies became accustomed to an extraordinary condition: money was cheap. Governments could borrow heavily, companies could finance expansion at modest rates, asset prices could rise on abundant liquidity, and households learned to treat low-cost mortgages as something approaching economic normality. That world is disappearing fast. Across major economies, long-term government borrowing costs have climbed towards levels not seen for years or decades. On 17 August, the US 30-year Treasury yield reached roughly 5.31 per cent, its highest level since 2007. Japan’s 10-year government bond yield subsequently approached 2.95 per cent, a three-decade high, while German borrowing costs have risen to 15-year highs. The OECD describes the present combination of elevated financing requirements and elevated yields as exceptional compared with the previous two decades. Behind those numbers is a larger structural contest. Governments need capital for debt refinancing, defence, infrastructure, pensions, healthcare and climate resilience. Technology companies require extraordinary sums for artificial-intelligence infrastructure. Energy systems require grids, generation and storage. Businesses require investment. Families require mortgages and credit. These demands do not occupy separate universes. They ultimately encounter the same fundamental economic resource: capital. And when many powerful institutions want more of it simultaneously, the price of money stops being an obscure financial-market variable. It becomes a question of who gets financed, at what price, and at whose expense.

For more than a century, the word vaccine has largely meant prevention: teach the immune system to recognise a threat before disease takes hold. Cancer is forcing medicine to reconsider that architecture. A new generation of experimental therapies is attempting something considerably more individual: sequence a patient’s tumour, identify mutations particular to that cancer, manufacture instructions corresponding to selected tumour-specific targets, and teach the patient’s immune system to recognise what belongs to the cancer growing inside that particular body. On 19 August, Moderna and Merck announced that their Phase III trial of the investigational personalised mRNA therapy intismeran autogene, used with Merck’s checkpoint inhibitor Keytruda after surgery for high-risk melanoma, achieved statistically significant and clinically meaningful improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone. The global trial enrolled 1,137 patients with resected stage IIB–IV melanoma. No new safety concerns were identified in the announcement. Full detailed Phase III results remain pending. The result matters because this is not simply another medicine administered to everyone carrying the same diagnosis. Intismeran is designed individually. Tumour and normal tissue are sequenced; mutations are analysed computationally; selected neoantigens — abnormal molecular features produced by the tumour — become the targets encoded into an mRNA therapy manufactured for that patient. Earlier Phase IIb evidence provides important context rather than a substitute for the unreleased Phase III detail. At five-year median follow-up, Moderna and Merck reported that intismeran plus Keytruda reduced the risk of recurrence or death by 49 per cent and distant metastasis or death by 59 per cent compared with Keytruda alone in that smaller study. The larger significance therefore extends beyond melanoma. Medicine has spent generations classifying disease so that patients with sufficiently similar conditions can receive sufficiently similar treatments. Personalised cancer vaccines suggest a different possibility: the diagnosis may identify the disease, while the tumour itself helps design the medicine. If that model succeeds across cancers, one of medicine’s great industrial achievements — standardisation — will begin coexisting with its apparent opposite: manufacturing treatment for one.